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https://doi.org/10.1016/j.cell.2020.07.025SUMMARYCell-surface protein-protein interactions (PPIs) mediate cell-cell communication, recognition, and re-
sponses. We executed an interactome screen of 564 human cell-surface and secreted proteins, most of
which are immunoglobulin superfamily (IgSF) proteins, using a high-throughput, automated ELISA-based
screening platform employing a pooled-protein strategy to test all 318,096 PPI combinations. Screen results,
augmented by phylogenetic homology analysis, revealed 380 previously unreported PPIs. We validated a
subset using surface plasmon resonance and cell binding assays. Observed PPIs reveal a large and complex
network of interactions both within and across biological systems. We identified new PPIs for receptors with
well-characterized ligands and binding partners for ‘‘orphan’’ receptors. New PPIs include proteins ex-
pressed on multiple cell types and involved in diverse processes including immune and nervous system
development and function, differentiation/proliferation, metabolism, vascularization, and reproduction.
These PPIs provide a resource for further biological investigation into their functional relevance andmay offer
new therapeutic drug targets.INTRODUCTION
Protein-protein interactions (PPIs) at the cell surface allow
cells to respond to one another and their environment in a
highly dynamic, context-dependent and spatiotemporal
manner (Wood and Wright, 2019). The essential role played
by cell-surface PPIs is exemplified by estimates that
20% of genes in the human genome encode cell-surface
proteins and 10% encode secreted proteins (Fonseca
et al., 2016).
At present, a comprehensive human cell-surface interactome
is lacking. Mapping extracellular PPIs has proved challenging
because most cell-surface proteins are refractory to classic
biochemical screening techniques and cell-surface PPIs are un-
derrepresented in affinity purification/mass spectrometry-based
datasets (Huttlin et al., 2015, 2017). Additionally, cell surface
PPIs often have fast binding kinetics spanning a broad range
of affinities (low nM to hundreds of mM) (van der Merwe and Bar-
clay, 1994), rendering them difficult to detect using standard
biochemical assays.In recent years, several assays have been developed that
allow detection of low-affinity cell-surface PPIs by imparting
avidity through clustering of secreted proteins and the extracel-
lular domains (ECDs) of single transmembrane (STM) cell-sur-
face proteins. Clustering is achieved using multimerization do-
mains, and can increase binding signal up to 250-fold (Bushell
et al., 2008). Experimental platforms that utilize clustering
include several variations of ELISA-based binding assays
(Wojtowicz et al., 2007; Bushell et al., 2008; Özkan et al.,
2013), Bio-Plex beads (Li et al., 2017), protein microarrays (Sun
et al., 2012), cell-signaling assays (Barrow et al., 2018), cell-sur-
face staining microarrays (Turner et al., 2013), and bead-based
assays (Husain et al., 2019). Multiple groups have shown that
ELISA-based binding assays have a remarkably low false-posi-
tive rate (Wojtowicz et al., 2007; Bushell et al., 2008; Söllner
andWright, 2009;Martin et al., 2010; Crosnier et al., 2011; Özkan
et al., 2013; Visser et al., 2015; Ranaivoson et al., 2019).
Previously, we conducted a screen for all 200 Drosophila
cell-surface and secreted proteins containing three types of do-
mains: immunoglobulin (Ig) and Ig-like, fibronectin type III (FN3),Cell 182, 1027–1043, August 20, 2020 ª 2020 Elsevier Inc. 1027
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Resourceand leucine-rich repeats (LRRs) (Özkan et al., 2013). This screen
reported over 80 new PPIs, including a previously unknown
immunoglobulin superfamily (IgSF) PPI network between mem-
bers of the Dpr and DIP subfamilies. Since we reported the
Dpr-DIP network, functional studies have revealed that this
network mediates neuronal wiring decisions in the fly brain and
neuromuscular system (for review, see Honig and Shapiro,
2020; Sanes and Zipursky, 2020).
In humans, there are an estimated 4,000 secreted and STM
proteins, totaling 8 M putative PPIs. Screening this vast num-
ber requires a high-throughput assay. Here, we developed a
screening platform that combines a high-throughput version of
the ELISA-based extracellular interactome assay (ECIA) (Özkan
et al., 2013) with an automated pooled-protein strategy (apE-
CIA). We performed a screen of human IgSF secreted and
STM cell-surface proteins (excluding antibodies and T cell re-
ceptors), along with other select proteins of interest. The IgSF
is the largest and most functionally diverse family in the cell-sur-
face proteome. Members include receptor tyrosine kinases,
phosphatases, co-stimulatory or co-inhibitory immune recep-
tors, growth factor and adhesion receptors, amongmany others,
and are present in most, if not all, cell types.
We produced 564 proteins, and screened every possible PPI
(564 3 564 = 318,096). We observed 426 PPIs, of which 345
(81%) are previously unreported. New PPIs form a complex
network and include PPIs between phylogenetically related pro-
teins within a subfamily, different subfamilies, and distantly
related proteins. Screen results were combined with phyloge-
netic homology analysis (PHA) to predict additional PPIs be-
tween subfamily members using a nearest-neighbor approach.
We confirmed a subset of both screen and PHA predicted
PPIs using surface plasmon resonance (SPR) and cell binding
assays.
RESULTS
Selection and Production of Proteins for PPI Screening
To identify human IgSF proteins, we utilized the HUGO Gene
Nomenclature Committee (HGNC) (Yates et al., 2017), Human
Protein Atlas (Uhlén et al., 2015), and UniProt (UniProt Con-
sortium, 2019) databases. ECDs and secreted proteins for 458
IgSF and 106 non-IgSF proteins of interest were produced with
‘‘bait’’ and ‘‘prey’’ multimerization domains into cell supernatants
(Figures 1A and 1B; Data S1 and S2) and expression was
confirmed by western blot (Data S3). Westerns revealed detect-
able levels of protein for 82% of baits and 70% of preys. We and
others have observed that PPIs can be detected in the ECIA and
other ELISA-based binding assays even when proteins are pre-
sent at levels below the limit of detection by western (Özkan
et al., 2013; Visser et al., 2015; Ranaivoson et al., 2019). As
such, all bait and prey were included in the screen regardless
of whether protein was detected.
Development of an Automated Pooled-Prey ECIA
Platform (apECIA)
ECIA and other ELISA-based assays allow bait and prey
proteins to be tested for binding directly from conditioned
media (Figure 1B). These assays test one bait-prey pair per1028 Cell 182, 1027–1043, August 20, 2020well. To increase throughput, we pooled three preys and,
following screening, deconvoluted positive wells to identify
PPIs (Figure 1B). Pooling experiments with a panel of known
PPIs showed binding for all 3-fold diluted prey (Figures 1C,
S1C, and data not shown). As bait-prey pairs are tested
in both orientations, a false-negative resulting from pooling
can be ‘‘rescued’’ by a positive result in the converse
orientation. We reasoned that the advantages of pooling,
which reduces the number of binding reactions, outweighed
the potential increase in false negatives. To further improve
throughput, we optimized a 384-well format and developed
an automated workflow using liquid handling robots. The
apECIA platform allows testing of 55,296 bait-prey combina-
tions per week.
PPI Screen Reveals a Complex Network of PPIs
Following screening, deconvolution of positive wells (R2 fold-
over-background) was performed by re-testing each prey
individually (Figure 1B). Nine prey gave rise to large numbers of
wells with positive signals and were excluded as non-specific
binders (Figure S2). Following removal of non-specific PPIs, de-
convolution revealed 495 positive wells comprising 426 unique
PPIs (Data S4). In each case, only one of the three deconvoluted
prey yielded a positive signal. To confirm binding, the positive
prey was re-tested against its cognate bait in triplicate.
Eighty-one percent (345/426) of PPIs are between IgSF proteins.
The remaining 19% include PPIs between IgSF and other
proteins present in the screen (Figure S3).
Almost half of the proteins tested were involved in a PPI
(254/564, 45%). Proteins not involved in PPIs may be mis-
folded, have binding partners not included in the screen,
require co-receptors, or fall outside the dynamic range of the
assay (false negatives) which is determined by PPI affinity
and bait and prey concentrations (Figure S4F). Confirming the
sensitivity of the assay, many bait or prey proteins expressed
at very low levels still engaged in one or two PPIs (Figures
S4A and S4B). A small number of PPIs were observed with
bait or prey proteins exhibiting undetectable levels in condi-
tioned media (Figures S4C–S4E). To interrogate the dynamic
range of the assay we plotted prey AP levels for PPIs with re-
ported affinities (Figure S4F). These data suggest that, for
very poorly expressed prey proteins (Figures S1A, S4A, and
S4B), PPIs with KD >4.5 mM are likely to be missed (false neg-
atives; Figure S4F).
Of the 426 PPIs, 345 (81%), are previously unreported based
on literature and PPI databases (Data S4). The majority of PPIs
(408/426) form one large network comprising 226 proteins
(Figure 1D). Only 28 proteins involving 18 PPIs are not connected
to the network. Different regions of the network are shown in
Figure 2. Ninety-eight proteins (39%) had one PPI, 113 (44%)
had two to five PPIs, and 43 (17%) had >5 PPIs (Figure 1E).
Because 45% of proteins exhibit binding, we calculated the
expected frequency with which each protein will bind at least
‘‘x’’ number of proteins up to the maximally observed 16 PPIs
(Figure S2B) and compared the expected and observed fre-
quencies (Figure 1F). The observed number of binding partners
is significantly greater than predicted by random chance of
PPIs for a network of this size.
A
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Figure 1. apECIA Screen Details and Overview of Results
(A) Schematic depiction of a subset of proteins in library. Pie graph of library distribution. Full protein domain names at http://smart.embl.de/ (Sun et al., 2012).
(B) Left: flow chart of screen. HT, high-throughput. Right: example plate from screen. Schematic of ECIA and pooled-prey strategy. Illustration of screen matrix.
(C) ECIA of undiluted prey (single prey) versus 3-fold diluted prey (pooled prey). Background subtracted data are represented as ±SD. Bkgd, background.
(D) Network of PPIs observed in screen. Inset: the 18 PPIs that are not connected to the network. Node size is proportional to number of PPIs. Siglec subfamily
nodes are highlighted in color.
(E) Pie graph of distribution of the number of binding partners observed in screen overlaid on the network in a degree-sorted circular layout.
(F) Observed versus expected frequency with which each protein will bind at least ‘‘x’’ number of proteins up to the maximally observed PPIs assuming random
chance of interactions (p = 0.01; Kolmogorov-Smirnov [K-S] test).
See also Figures S1, S2, S3, and S4 and Data S1, S2, S3, and S4.
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PPIs often occur between phylogenetically related proteins both
within and between subfamilies. We performed multiple
sequence alignments to identify subfamily members within our
library and generated phylogenetic trees. Using a combined
approach, which we call apECIA-PHA, we analyzed screen
data alongside the phylogenetic trees to predict additional
PPIs between subfamily members that may have been missed
in the screen.
PPI Validation by Surface Plasmon Resonance
We selected a subset of screen and PHA predicted PPIs to vali-
date by SPR. Bona fide PPIs are expected to display distinct as-
sociation and dissociation, which can be observed with high
sensitivity by SPR. To increase avidity, and therefore sensitivity,
Fc dimerized ECDanalytes and ligandswere used inmost exper-
iments (Figure S5). This increase in sensitivity prevented us from
determining monomeric KD constants. Binding profiles charac-
teristic of PPIs, exhibiting clear resonance signals above back-
ground (negative control ligand and receptor) and concentra-
tion-dependent binding curves, were deemed indicative of a
specific ligand-analyte PPI. Non-specific PPIs generally exhibit
deviations from this behavior, such as high background and
non-linear concentration responses.
Twenty-four newly identified PPIs observed in our screen were
tested by SPR. Of these, we observed 23 specific ligand-analyte
interactions. We additionally tested 35 PHA predicted PPIs and
observed PPIs for 33. Three additional PPIs were observed be-
tween homologous proteins in mouse and cross-species (hu-
man-mouse). In total, we SPR validated 59 newly identified
PPIs (Table 1; Data S5).
Combined apECIA-PHA Approach Reveals Multiple DCC
Subfamily PPIs
The netrin-1 receptor DCC has well-characterized functions in
the nervous system (Finci et al., 2015). DCC is a dependence re-
ceptor and is implicated in colorectal and other cancers, but its
roles in these cancers are not well understood (Goldschneider
and Mehlen, 2010). We observed DCC binding to insulin-like
growth factor-binding protein-like 1 (IGFBPL1), but not to insu-
lin-like growth factor-binding protein 7 (IGFBP7) (Figures 2I and
3A). Our phylogenetic tree revealed IGFBPL1 and IGFBP7 reside
in a cluster and share the highest amino acid sequence similarityFigure 2. Select Regions of the Complex PPI Network
(A) Select PPIs including four proteins not connected to the network (CD146, CN
(B) Region largely comprised of immune system proteins.
(C) Region comprising PPIs both within and across biological systems.
(D) Two regions highlighting subfamily-specific type IIA and type IIB PTPR PPIs. T
predicted PPIs validated by SPR (Figures 4 and S6).
(E) Region highlighting PPIs for ‘‘orphan’’ receptors ILDR1 and PUNC.
(F) Region showing a subset of LILR subfamily PPIs.
(G) Region showing a subset of Siglec PPIs with non-Siglecs (CD33/Siglec-3).
(H) Region showing Siglec-Siglec PPIs (CD33/Siglec-3; MAG/Siglec-4a; SN/Sigl
(I) Region highlighting PPIs between nervous system proteins and with proteins in
predicted PPIs were validated by SPR (Figure 3; Table 1).
Because a network is composed of interconnected nodes, some linkage proteins
validated by additional experiments. Green line, previously reported PPI; gray lin
See also Data S4.(55%) among subfamily members. As such, we examined bind-
ing of DCC to both IGFBPL1 and IGFBP7 by SPR and observed
binding for both (Figure 3C).
PHA pointed us to four proteins that cluster with DCC: PUNC,
PUNC e11, neogenin (NEO1), and protogenin (PRTG) (Figure 3A).
Together, these proteins play roles in diverse processes
including nervous system development, myogenesis and angio-
genesis, inflammation and tissue regeneration, leukocyte migra-
tion, neural tube and mammary gland formation, development of
bone and connective tissues, and stem cell differentiation (Sal-
baum, 1998; Wilson and Key, 2007; Takahashi et al., 2010;
Schievenbusch et al., 2012; Dakouane-Giudicelli et al., 2014).
PUNC is an ‘‘orphan’’ receptor expressed in the developing ner-
vous system (Salbaum, 1998). PUNC e11 andPRTGbound inter-
cellular adhesion molecule 5 (ICAM5) (Figure 3A), a protein
exclusively expressed in the brain that functions in synapse for-
mation, stabilization, and refinement (Gahmberg et al., 2014).
Cleaved ICAM5 ECD exhibits immunosuppressive functions
through cytokine regulation and may play important roles in
regulation of brain inflammation. We confirmed binding of
PUNC e11 and PRTG to ICAM5 by SPR (Figure 3C). Although
PPIs with ICAM5 were not detected in the screen for the remain-
ing DCC subfamily members, we tested them by SPR and
observed binding for all three (Figure 3C).
In our screen, one or more DCC subfamily members also
bound to: (1) WFIKKN2, a secreted protein that binds transform-
ing growth factor-beta subfamily members and modulates their
presentation to cells (Monestier and Blanquet, 2016), (2) lacto-
transferrin (LTF), an iron-binding protein with antimicrobial activ-
ity (Hao et al., 2019), (3) interleukin-6 receptor subunit alpha (IL-
6Ra), a cytokine receptor (Schaper and Rose-John, 2015), and
(4) ISLR2/LINX, which functions in nervous system development
(Mandai et al., 2014; Panza et al., 2015; Abudureyimu et al.,
2018). We confirmed binding of all DCC subfamily members to
these proteins by SPR and to other proteins observed in our
screen (Figures 3C, 3D, and 3F). These results demonstrate
the value of using a combined apECIA-PHA approach to identify
additional PPIs beyond screen data, resulting in the elucidation
of a more complete network (Figure 3F).
LAR-PTPR Subfamily PPIs with SALMs
The LAR-family of type IIA protein tyrosine phosphatase recep-
tors (LAR-PTPRs) comprises PTPRF (also known as LAR),TN1, NFASC, and NrCAM).
ype IIA PPIs with SALMs and IL1APs include PPIs observed in screen and PHA
ec-1).
immune and reproductive systems. Within this region, multiple additional PHA
are present in more than one panel. Colored nodes denote proteins and PPIs
e, previously unreported PPI.
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Table 1. SPR-Validated apECIA Screen and PHA Predicted PPIs
Ligand-Fc Analyte-Fc apECIA PHA
TIE1 TrkA + N/A
hISLR2 hLEPa + N/A
mLepa N/A +
mIslr2 hLEPa N/A +
mLepa N/A +
SALM1 PTPRD N/A +
PTPRF N/A +
PTPRS N/A +
SALM2 PTPRD known N/A
PTPRF + N/A
PTPRS + N/A
SALM3 PTPRD known N/A
PTPRF + N/A
PTPRS known N/A
SALM4 PTPRD N/A +
PTPRS N/A +
SALM5 PTPRD known N/A
PTPRF known N/A
PTPRS known N/A
IL1RAPL1 PTPRS + N/A
IL1RAPL2 FGFR3 + N/A
PTPRS + N/A
DSCAM-CT PTPRM + N/A
PTPRT + N/A
DSCAML1-CT PTPRM + N/A
PTPRT + N/A
KIR2DL5 PVR known N/A
IL-6Ra ISLR2 + N/A
PSG7 DCC + N/A
DSCAM + N/A
PSG9 DSCAM + N/A
ICAM5 DCC N/A +
IL-6Ra N/A +
ISLR2 N/A +
NEO1 N/A +
PRTG + N/A
PUNC N/A +
PUNC e11 + N/A
WFIKKN2 DCC N/A +
IL-6Ra N/A +
ISLR2 N/A +
PRTG + N/A
PUNC + N/A
PUNC e11 + N/A
PD-L1 PD-L1 N/A +
PD-L2 PD-L1 known N/A
LTF DCC N/A +
IL-6Ra N/A +
(Continued on next page)
Table 1. Continued
Ligand-Fc Analyte-Fc apECIA PHA
ISLR2 N/A +
NEO1 N/A +
PRTG N/A +
PUNC N/A +
PUNC e11 + N/A
IGFBPL1 DCC + N/A
IL-6Ra N/A +
ISLR2 N/A +
NEO1 N/A +
PRTG N/A +
PUNC N/A +
PUNC e11 N/A +
IGFBP7 DCC N/A +
IL-6Ra N/A +
ISLR2 N/A +
NEO1 N/A +
PRTG N/A +
PUNC N/A +
PUNC e11 N/A +
ECD-Fc ligand and ECD-Fc analyte PPIs observed by SPR. apECIA de-
notes PPI was observed in screen. PHA denotes PPI was predicted by
phylogenetic homology analysis. SPR conditions are included in Data
S5. See also Figure S6.
ahLEP and mLEP, monomer protein.
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important roles in synaptic organization and function (Nam
et al., 2011). Pre-synaptic LAR-PTPRs mediate trans-synaptic
adhesion through PPIs with multiple post-synaptic ligands.
Mouse mutants in LAR-PTPRs and their ligands exhibit defects
in synapse structure and function (Lie et al., 2018).
Several PPIs are known between specific LAR-PTPRs and
SALM2/3/5 (Li et al., 2015; Choi et al., 2016; Goto-Ito et al.,
2018) (Figure 4A). We observed these, as well as additional
PPIs in our screen (Figures 2D, 4A, and 4C). No LAR-PTPR bind-
ing to SALM1 or SALM4 has been reported, and we did not
observe binding in our screen. PHA led us to test binding of all
LAR-PTPRs to all SALMs by SPR. With the exception of
PTPRF-SALM4, we observed binding of all LAR-PTPRs to all
SALMs (Figures 4E and S6A). PTPR-SALM pairs exhibited differ-
ences in maximum response units (RU), a relative comparison of
binding strength, suggesting a spectrum of binding affinities may
exist among LAR-PTPRs and SALMs (Figure 4F).
LAR-PTPR Subfamily PPIs with Interleukin-1 Receptor
Accessory Proteins (IL1APs)
Trans-synaptic LAR-PTPR interactions with IL1RAP and IL1-
RAPL1 induce bidirectional pre- and post-synaptic differentia-
tion (Yoshida et al., 2011, 2012). IL1RAP is known to interact
with all three LAR-PTPRs and IL1RAPL1 with PTPRD. We
observed these PPIs and, additionally, binding of IL1RAPL1 to
PTPRS (Figure 2D). IL1RAPL1 shares 79% sequence similarity
A B
C
D E F
(legend on next page)
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no known biological function (Boraschi et al., 2018). In our
screen, we detected binding of IL1RAPL2 to PTPRD and PTPRS
(Figure 2D). We tested both known and previously unknown PPIs
by SPR and observed binding for all (Figure S6B). IL1RAPL2
additionally interacted with fibroblast growth factor receptor 3
(FGFR3) in the screen and by SPR (Figure S6B).Type IIB PTPR Subfamily PPIs with DSCAMs
Type IIB PTPRs are expressed in most tissues and regulate
diverse processes including cell growth, migration, and differen-
tiation; immune cell development; endothelial cell adhesion and
migration; neuronal development and synapse formation; and
oncogenic transformation (Lee, 2015; Stoker, 2005). The type
IIB subfamily is composed of PTPRK, PTPRM, and PTPRT (Fig-
ures 4A and 4B), and multiple binding partners are known. We
observed binding of all type IIB PTPRs with Down syndrome
cell adhesionmolecule (DSCAM) and Down syndrome cell adhe-
sion molecule like-1 (DSCAML1) (Figures 4A and 4C), proteins
that play various roles in nervous system development (Sanes
and Zipursky, 2020).
The ECD of DSCAMs contains nine Ig-like domains followed
by four FN3 domains, one Ig-like domain, and two FN3 domains
(Figure 4B). The N-terminal region engages in homophilic binding
and mediates binding to secreted chemoattractant and chemo-
repellent ligands, netrin-1 and slit-1, respectively (Wojtowicz
et al., 2004; Ly et al., 2008; Alavi et al., 2016). No binding partner
has been reported for the C-terminal ECD region. In our screen,
we observed binding between the C-terminal regions of both
DSCAMs (DSCAM-CT and DSCAML1-CT) and all three type
IIA PTPRs (Figure 4C). We confirmed binding of DSCAM-CT
and DSCAML1-CT to PTPRT and PTPRM by SPR (PTPRK was
not expressed at sufficient levels) (Figure 4D).New PPIs between Immune System Proteins
New PPIs were observed for well-studied immune system
proteins, as well as orphan receptors (Figure 2B). Two PPIs
were detected for the orphan granulocyte receptor CEA-
CAM4: (1) vascular endothelial growth factor receptor 3
(VEGFR3), and (2) programmed cell death 1 ligand 2 (PD-
L2). CEACAM4 is a member of the carcinoembryonic anti-
gen-related cell adhesion molecule subfamily expressed in
the immune system, epithelial and endothelial cells, and brain
(Wakabayashi-Nakao et al., 2014; Zinn and Özkan, 2017). In
the immune system, CEACAMs play roles in immunity and
development. We also observed binding between CEACAM1Figure 3. SPR Validation of DCC Subfamily PPIs Identified by apECIA-
(A) Dendrograms of a subset of DCC subfamily PPIs showing the number of SPR-v
(magenta).
(B) Dendrogram of a subset of PSG PPIs.
(C) SPR sensorgrams for DCC subfamily, IL6-Ra, and ISLR2 analytes (2-fold
regeneration at higher concentrations) binding to various ligands. TrkA and TIE1
(D) SPR sensorgram for IL-6Ra analyte (2-fold dilutions; 2–2,048 nM) binding to
(E) SPR sensorgrams for DSCAM and DCC analytes (2-fold dilutions; 16–2,048 n
(F) Subnetwork of SPR-validated PPIs.
RU, resonance units.
See also Figure S5 and Data S5.
1034 Cell 182, 1027–1043, August 20, 2020and the immune checkpoint receptor, programmed cell death
protein 1 (PD-1).
Interactions of PD-1 with its ligands PD-L1 and PD-L2 inhibit
T cell proliferation, cytokine production, and cytotoxic activity
(Bardhan et al., 2016). PD-L2 competes with PD-L1 for binding
to PD-1 and can be expressed on tumor cells where it may
play a role in tumor evasion (Ghiotto et al., 2010; Cheng et al.,
2013; Bardhan et al., 2016). Using SPR, we confirmed the known
PPI between PD-L1 and PD-L2 (Lee et al., 2016) and observed
homophilic binding of PD-L1, a previously unknown PPI (Fig-
ure S6C). By comparison with PD-L1 binding to PD-1, which ap-
proaches saturation at 400 nM, we infer that the affinity of PD-
L1 homophilic binding is lower than binding to PD-1. This may
explain why this PPI within the well-studied PD-1/PD-L1 axis
has not been identified previously, and highlights the value of us-
ing multimerized proteins to detect low-affinity PPIs.
Homophilic and Heterophilic Siglec Subfamily PPIs
Eight of the proteins with the highest number of PPIs in our
screen are members of the Siglec subfamily (14 members), pro-
teins highly restricted to the immune system that have immune
modulatory effects on Toll-like receptor (TLR) signaling and
play important roles in self versus non-self discrimination (Mac-
auley et al., 2014). Siglecs display differential expression on cells
and exhibit a broad spectrum of Siglec-specific recognition of
sialylated glycan profiles present on healthy cells, inflamed or
malignant cells, and pathogens. We observed a network of ho-
mophilic and heterophilic PPIs among Siglecs (Figure 2H; Data
S4), as well as PPIs with distantly related proteins (a subset are
shown in Figure 2G; Data S4).
PPIs between Immune and Nervous System Proteins
The signaling lymphocytic activation molecule subfamily (SLAM;
9 members) is expressed on most immune cells (Dragovich and
Mor, 2018). SLAMs function as both co-stimulatory and co-
inhibitory molecules in innate and adaptive immunity, and play
an integral role in autoimmune disorders. SLAMF9 is an orphan
receptor.
We observed SLAMF9 binding to bactericidal permeability-
increasing protein (BPI) and IGSF10 (Figure 2C). BPI is a neutro-
phil-derived antibiotic protein that participates in bacteria killing
through its highly cationic N-terminal region (Bülow et al., 2018).
The C-terminal region of BPI exhibits no bactericidal activity and
is believed to interact with other proteins and function in different
processes. IgSF10 is an orphan receptor involved in the migra-
tion of gonadotropin-releasing hormone expressing (GnRH) neu-
rons (Howard et al., 2016). IgSF10 has no known function in thePHA Approach
alidated PPIs observed in the apECIA screen (turquoise) and predicted by PHA
dilutions; 2–2,048 nM; 512 nM for PRTG:WFIKKN2 due to incomplete chip
, negative controls.
ISLR2 ligand. PUNC, negative control.
M) binding to PSG ligands. TIE1, negative control.
A
B
C D
FE
(legend on next page)
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unknown, revealing a PPI between two orphan receptors from
different biological systems.
PPIs with Pregnancy-Specific Glycoproteins (PSGs)
During pregnancy, PSGs (10 members) are the most abundant
trophoblastic proteins in maternal blood and serve as markers
for trophoblast quality and embryo viability (Moore and Dveksler,
2014). The mechanisms of PSG action in pregnancy are not well
understood. Studies suggest PSGs also have immunoregula-
tory, pro-angiogenic, and anti-platelet aggregation functions.
We observed several PSG binding partners including: (1)
platelet-derived growth factor receptor alpha (PDGFRA), (2)
fibroblast growth factor receptor 4 (FGFR4), (3) C-type lectin
domain family 4 member A (CLEC4A), (4) DCC, and (5) DSCAM
(Figures 2I and 3B).
Observed PSG interactions occur selectively and differentially
to these binding partners (Figure 2I; Data S4). Using SPR, we
examined binding of DCC and DSCAM to PSG7 and PSG9 (Fig-
ure 3E). We observed binding for DSCAM with PSG9, and both
DCC and DSCAM with PSG7. Interestingly, DCC is expressed
in human placenta (Dakouane-Giudicelli et al., 2014). These
PPIs present new candidate receptors for studying the role of
PSGs in pregnancy, immunoregulation, and angiogenesis.
LILR Subfamily PPIs with BTNL8 and Myelination
Proteins
Leukocyte immunoglobulin-like receptors (LILRs; 11 members)
are a subfamily of activating (LILRA) and inhibitory (LILRB) recep-
tors that exhibit immunomodulatory activity and function in
inflammation regulation, tolerance, and differentiation (Burshtyn
and Morcos, 2016). We observed binding of multiple activating
and inhibitory LILRs to butyrophilin-8 (BTNL8) (Figure 2F). BTNLs
are members of the extended B7 family of molecules and func-
tion as co-stimulatory or co-inhibitory signals for T cell activation
(Rhodes et al., 2016).
LILRs are also expressed on neurons and function in the regu-
lation of development, synaptic plasticity, and axonal regenera-
tion (Hirayasu and Arase, 2015). Myelin, the protective insulating
layer around axons, inhibits neuronal regeneration following spi-
nal injury (Monje, 2018). Three myelin proteins, Nogo, MAG, and
OMgp, are known to interact with PirB in mouse, one of only two
mouse LILRB orthologs (Atwal et al., 2008).We observed binding
of multiple LILRs to two additional myelin proteins: myelin-oligo-
dendrocyte glycoprotein (MOG) and myelin protein P0 (MPZ)Figure 4. SPR Validation of Type IIA and Type IIB PTPRs with SALMs a
(A) Left: dendrogram highlighting phylogenetic clustering of SALMs, DSCAMs,
validated PPIs: green line, previously known PPI; turquoise line, previously unkno
PPI. Gray line, screen PPI not SPR tested.
(B) Protein domain structures. Ig, immunoglobulin-like domain; FN, fibronectin typ
transmembrane; NT, N-terminal region of ECD; CT, C-terminal region of ECD.
(C) Screen data showing PPI specificity of PTPRF/S/D and PTPRT/M/K subfam
triplicate wells.
(D) SPR sensorgrams for DSCAML1-CT and DSCAM-CT analytes (2-fold dilution
(E) SPR sensorgrams for PTPRS analyte (2-fold dilutions; 2–2,048 nM) binding to
(F) SPR max RU values for every pairwise combination of PTPRF/S/D analytes w
RU; resonance units.
See also Figures S5 and S6 and Data S5.
1036 Cell 182, 1027–1043, August 20, 2020(Figure 2F). These PPIs present MOG and MPZ PPIs with LILRs
as new candidates for neuronal regeneration studies.
PVR Selectively Interacts with a Killer-Cell
Immunoglobulin-like Receptor (KIR)
The polygenic Killer-cell immunoglobulin-like receptors (KIRs)
are a highly polymorphic subfamily of activating and inhibitory
proteins expressed on natural killer (NK) cells that regulate devel-
opment, maturation, and activation (Pende et al., 2019). NK cells
initially express a stochastic combination of KIRs that is refined
during maturation to tune killing response threshold and ensure
optimal discrimination of target cells from healthy cells. We
observed binding of KIR2DL5 to poliovirus receptor (PVR) (Fig-
ures 2C and 5A), which validates a recently reported PPI (Husain
et al., 2019). We confirmed KIR2DL5 binding to PVR by ECIA
titration analysis and SPR (Figures 5C and 5D).
To examine binding at the cell surface, fluorescent tetramers
of PVR-Fc and KIR2DL5-Fc (ECD-Fc:SA-647) were incubated
with full-length KIR2DL5- and PVR-transfected cells, respec-
tively. Flow cytometry analysis revealed concentration-depen-
dent binding of both ligands to cells expressing cognate full-
length receptor, but not control cells (Figure 5E). PVR-Fc tetra-
mers did not bind cells transfected with full-length KIR2DL4
and KIR2DL1, which share 87% and 69% sequence similarity
with KIR2DL5, respectively (Figures 5B and 5F). To further
examine the specificity of PVR for KIR2DL5, ECIA was per-
formed using 11 KIRs. PVR bound specifically to KIR2DL5 (Fig-
ure 5G). Because KIR2DL5 has been associated with increased
virus susceptibility and reduced anti-viral response to therapy,
this specificity may have implications for the role of KIR2DL5 in
immunity.
TrkA Selectively Interacts with TIE1
High-affinity nerve growth factor receptor (NTRK1), also known
as TrkA, has multiple well-studied functions in the nervous sys-
tem (Amatu et al., 2019). In the immune system, where its func-
tion is not well understood, TrkA is expressed on monocytes,
macrophages, dendritic cells, resting and activated B cells and
neutrophils, and erythroblasts (Minnone et al., 2017). In our
screen, we observed TrkA binding to tyrosine-protein kinase re-
ceptor TIE1, but not to TIE2 (Figures 2A and 6A). TIE1 is ex-
pressed on endothelial cells, immature hematopoietic cells and
platelets, and functions in complex with the angiopoietin-TIE2
pathway to inhibit angiogenesis (Eklund et al., 2017). We per-
formed SPR and observed TrkA binding to TIE1, but not tond DSCAMs
type IIA PTPRs (PTPRF/S/D), and type IIB PTPRs (PTPRT/M/K). Right: SPR-
wn PPI observed in screen; magenta line, previously unknown PHA predicted
e III domain; MAM, meprin, A-5 protein domain; LRR, leucine-rich repeat; TM,
ilies. Background subtracted O.D. 650 nm data are represented as mean of
s; 16–2,048 nM) binding to PTPRM and PTPRT ligands.
SALMs and DSCAM-CT ligands.
ith SALM ligands.
A
B
C
E F G
D
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confirmed binding to monomer angiopoietin-1 (Figure S7A) (Da-
vis et al., 1996).
We next investigated whether TrkA can bind NGF and TIE1
simultaneously. We pre-incubated TrkAwith NGF and compared
binding of TrkA ± NGF to TIE1 via SPR (Figure 6B). Compared
with TrkA alone, TrkA:NGF binding to TIE1 exhibited an increase
in max RU corresponding to the molecular weight of NGF di-
mers, demonstrating that NGF-bound TrkA can interact with
TIE1. We tested TrkA-Fc tetramer binding to full-length TIE1-
transfected cells and observed concentration-dependent bind-
ing to TIE1-transfected but not control cells (Figure 6C). TrkA
interaction with TIE1may play a role in angiogenesis and/or other
biological processes.
Leptin Interacts with ISLR2
Leptin is a cytokine predominantly secreted by adipose cells and
enterocytes in the small intestine and is required for the mainte-
nance of energy homeostasis and bodyweight (Friedman, 2016).
The function of leptin in this process is mediated by binding to
the leptin receptor (LEPR) in a subtype of hypothalamic neurons.
Leptin deficiency results in various metabolic disorders and rare
genetic defects. The role of leptin in regulation of fat stores is its
most highly studied function. However, leptin is secreted by
many other types of cells and LEPR is expressed in other
neuronal subtypes and non-neuronal cells suggesting leptin
plays roles in additional processes.
We observed leptin binding to neuronally expressed ISLR2
(Figure 2A) (Mandai et al., 2014). The ECD of ISLR2 contains
seven LRRs followed by three Ig-like domains (Figure 6D). To
map the region of ISLR2 where leptin binds, we generated two
ECD truncations comprising LRR1-7 and Ig1-3 and measured
leptin binding using ECIA. Leptin bound equivalently to the entire
ECD and LRR1-7. No binding was observed to Ig1-3 (Figure 6E).
We tested leptin-Fc tetramer binding to full-length ISLR2-trans-
fected cells and observed concentration-dependent binding to
ISLR2-transfected but not control cells (Figure 6F).
As Lep/mice are a well-studiedmodel of obesity (Friedman,
2016), we tested human leptin binding tomouse Islr2 using ECIA.
Human leptin bound mouse Islr2 (Figure 6G). We then measured
the binding affinities of monomer human and mouse leptin to
both human ISLR2 andmouse Islr2 using SPR (Figure 6I). In con-
trols, human and mouse leptin bound their cognate LEPR and
Lepr with affinities in agreement with the range of published KDFigure 5. PVR Specifically Interacts with KIR2DL5
(A) Protein domain structures of KIR2DL5 and PVR.
(B) Dendrogram showing KIR family members in screen. KIRs outlined in orange
(C) ECIA titration of PVR-5AP on KIR2DL5-Fc (left) and KIR2DL5-Fc on PVR-5A
represented as mean ± SD.
(D) SPR sensorgram and steady-state curve for PVR analyte (2-fold dilutions; 15
(E) Cell staining of full-length KIR2DL5-transfected and control cells with PVR-Fc
Fc:SA-647 (bottom) and analysis by flow cytometry. Data are represented as me
(F) Top: cell staining of full-length transfected KIR2DL5, KIR2DL4, KIR2DL1, an
cytometry. Bottom: flow cytometry analysis of anti-His-647 stained cells. Data a
(G) Top: ECIA of PVR-5AP with 11 KIR ECD-Fc baits. Background subtracted dat
analysis of KIR-Fc proteins on ELISA plate.
RU, resonance units; MFI, mean fluorescence intensity; Ig, immunoglobulin-like
See also Figure S5 and Data S5.
1038 Cell 182, 1027–1043, August 20, 2020values (Verkerke et al., 2014) (Figure S7B). To investigate
whether leptin can bind ISLR2 and LEPR simultaneously, we
pre-incubated leptin with LEPR and compared binding of
leptin ± LEPR to ISLR2 via SPR. Compared with leptin alone,
leptin:LEPR exhibited no binding to ISLR2, suggesting that leptin
cannot bind LEPR and ISLR2 simultaneously (Figure 6H). To
assess whether this decrease in leptin binding to ISLR2 occurs
in a LEPR concentration-dependent manner, we pre-incubated
leptin with increasing concentrations of LEPR. Leptin binding
to ISLR2 decreased as LEPR concentration increased (Fig-
ure 6H). ISLR2 interaction with leptin presents a candidate PPI
for future studies into the function of leptin in the regulation of
fat stores or other physiological processes, and in leptin defi-
ciency diseases.
DISCUSSION
Elucidation of the map of extracellular PPIs is essential to under-
standing the role of cell-surface PPIs in both healthy and disease
tissues. Our screen revealed a highly connected and complex
network of PPIs. This dataset provides a deep resource for further
investigation. We anticipate it will provide candidates for the
broader research community to interrogate the function of these
PPIs in many biological systems. The complete list of PPIs (Data
S4) contains many that have not been described in the Results.
The approaches for selecting PPIs to investigate are multiple
and varied. Below, we discuss the strategies that guided our
exploration.
Homology-Guided Exploration of PPIs
Using a phylogenetic homology pipeline, we were able to expand
upon our screen results by predicting and testing additional sub-
family PPIs. This revealed an effective strategy to maximize the
number of PPIs identified. Homology-guided identification of pro-
tein subfamilies was also important to correctly classify subfamily
PPIs. For instance, in the absence of phylogenetic analysis, we
may not have identified CD33, SN, and MAG as members of the
Siglec subfamily. This demonstrates that phylogenetic analysis
of PPIs is important to ensure completeness of networks.
Homology-guided exploration can reveal new pathways to
investigate. As each PPI branches to include interactions with
one or more proteins, homology-guided investigation results in
a ‘‘domino effect,’’ revealing increasingly complex branching
patterns of interconnected PPIs. We used this approach towere tested in (G).
P (right). Images are scanned ELISA plates. Background subtracted data are
6–10,000 nM) binding to KIR2DL5 ligand.
:SA-647 (top) and full-length PVR-transfected and control cells with KIR2DL5-
an ± SD.
d control cells with PVR-Fc:SA-647 and control protein and analysis by flow
re represented as mean ± SD.
a are represented as mean ± SD. Bottom: following ECIA, anti-His western blot
domain; TM, transmembrane; Ctrl, control.
A
B
D
F
I
G H
E
C
Figure 6. TrkA Interacts with TIE1 and Leptin Interacts with ISLR2
(A) Protein domain structures of TrkA and TIE1.
(B) Left: SPR sensorgram for TrkA analyte (2-fold dilutions; 2–2,048 nM) binding to TIE ligand. Right: SPR sensorgram for 100 nM TrkA analyte ± 128 nM NGF
binding to TIE1 ligand.
(C) Cell staining of full-length TIE1-transfected and control cells with TrkA-Fc:SA-647 and analysis by flow cytometry. Data are represented as mean ± SD.
(legend continued on next page)
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gating new PPIs that exhibit one degree of separation. These re-
vealed linked PPI pathways between proteins with two degrees
of separation. Our findings illustrate that each newly identified
PPI has the potential to create additional interconnected
branches within the network.
A quick survey of screen data reveals multiple phylogenetic
pathways that can be explored in the future. It must, however,
be noted that some proteins engage in a highly specific PPI
with only one subfamily member. Our finding that PVR specif-
ically binds KIR2DL5, but none of the other KIRs examined, illus-
trates this point.
Functional-Guided Exploration of PPIs
Functional homology can be used to guide exploration in cases
where PPIs are observed with proteins belonging to different,
distantly related subfamilies. In this approach, proteins are clus-
tered by function, and PPIs are selected for investigation based
on sharedbiological processes. Using this approach,we identified
several PPIs of interest. For instance, LILRs interactwithMOGand
MPZ, two proteins that do not share significant sequence homol-
ogy but are both involved in the formation and maintenance of
myelin sheath. In another example for future studies, themegakar-
yocyte and platelet inhibitory receptor (G6b) bound advanced
glycosylation end product-specific receptor (AGER/RAGE) and
IGFBP7. These three proteins share no significant sequence ho-
mology, but all play roles in inhibition of platelet activation and ho-
meostasis and other vascular processes.
Expression-Guided Exploration of PPIs
Cell-type and tissue expression can be used to guide PPI explo-
ration in cases where proteins share no sequence homology and
where biological function within a system is unknown. In this
approach, proteins are clustered by expression and PPIs are
evaluated by shared expression, or by expression in cells that
encounter one another. Using these criteria, respectively, we
selected leptin-ISLR2 and TrkA-TIE1 for investigation. Expres-
sion-guided exploration of PPIs is limited by the availability and
resolution of mRNA and protein expression data and broad
expression across multiple tissues and cell types. As such,
expression-guided exploration is a useful tool for proteins that
exhibit more restricted expression patterns.
PPIs with Signaling-Competent Cell-Surface Proteins
Many PPIs in the screen were observed with signaling-compe-
tent proteins including receptor tyrosine kinases (RTKs), PTPRs,(D) Protein domain structures of ISLR2 ECD and truncations.
(E) ECIA of leptin-5AP with ISLR2 ECD-Fc, LRR1-7-Fc, and Ig1-3-Fc. Backgroun
(F) Cell staining of full-length ISLR2-transfected and control cells with leptin-Fc:S
(G) ECIA of human leptin-5AP with human ISLR2-Fc and mouse Islr2-Fc. LEPR-F
as mean ± SD.
(H) Left: SPR sensorgram for 128 nM leptin ± 256 nM LEPR analyte binding to IS
ligand following pre-incubation with increasing concentrations of LEPR (2-fold d
(I) SPR sensorgrams and steady-state curves for monomer human and mouse lep
Islr2 ligands.
RU, resonance units; MFI, mean fluorescence intensity; Ig, immunoglobulin-like do
growth factor repeat domain; TM, transmembrane; Ctrl, control.
See also Figures S5 and S7 and Data S5.
1040 Cell 182, 1027–1043, August 20, 2020ITIM-, and ITAM-containing proteins and proteins with B30.2 do-
mains (e.g., BTNL8). Interestingly, in some cases, both receptor
and ligand exhibit signaling capacity. PVR and KIR2DL5 are both
ITIM-containing inhibitory receptors. TrkA and TIE1 are both
RTKs. VEGFR3 is an RTK that bound CEACAM4, an ITAM-con-
taining activating receptor. In other cases, a ligand bound two re-
ceptors with the same signaling competence: PSGs bound two
RTKs, PDGFRA and FGFR4. Together, these signaling receptors
regulate a broad spectrum of pathways. As signaling receptors
are relevant targets across multiple cancers, these PPIs may
suggest new candidates for therapeutic investigation.
Therapeutic Relevance and Future Applications
In our screen, 60% of proteins with binding partners engaged
in >1 PPI. Several of these proteins are targets of current drugs,
including TrkA (cenegermin), Siglec-2 (Besponsa), PD-L1 (atezo-
lizumab, avelumab, and durvalumab), PTPRS (Adrovance and
Didronel), FGFR4 (pemigatinib), IL-6Ra (tocilizumab), and
VEGFR3 (axitinib), among others. Newly identified PPIs for these
targets suggest proteins that should be considered when inves-
tigating themechanisms of drug action as theymay contribute to
off-target effects or unanticipated signaling mechanisms. In
addition, previously unknown PPIs may lead to the discovery
of new alternative drug targets for clinically proven pathways
or mechanisms. Continued cell-surface PPI mapping is funda-
mental to understand the intricate networks that function in
health and disease.
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Özkan, E., Carrillo, R.A., Eastman, C.L., Weiszmann, R., Waghray, D., John-
son, K.G., Zinn, K., Celniker, S.E., and Garcia, K.C. (2013). An extracellular in-
teractome of immunoglobulin and LRR proteins reveals receptor-ligand net-
works. Cell 154, 228–239.
Panza, P., Sitko, A.A., Maischein, H.-M., Koch, I., Flötenmeyer, M., Wright,
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Mouse anti-His-647 R&D Systems Cat#IC0501R
Penta$His Antibody; BSA free QIAGEN Cat#34660; RRID:AB2619735
Polyclonal Rabbit-Anti-Mouse Immunoglobulin HRP Agilent Cat#P0161; RRID:AB2687969
Bacterial and Virus Strains
Mix & Go Competent Cells - Strain DH5 Alpha Zymo Research Cat#T3007
Chemicals, Peptides, and Recombinant Proteins
2-mercaptoethanol Thermo Fisher Scientific Cat#21985023
4-12% Bis-Tris NuAPGE Protein Gels Thermo Fisher Scientific Cat#NP0322
4–20% Criterion TGX Precast Midi Protein Gel Bio-Rad Cat#5671095
4–20% Mini-PROTEAN TGX Precast Protein Gels Bio-Rad Cat#4561096
Adenosine 50-triphosphate disodium Salt
Hydrate (ATP)
Sigma Cat#A2383-10G
Alexa Fluor 647 NHS Ester (Succinimidyl Ester) Thermo Fisher Scientific Cat#A37573
Alkaline Phosphatase Thermo Fisher Scientific Cat#31391
Amersham ECL Prime Western Blotting Detection
Reagent
Fisher Scientific Cat#45-002-401
Antibiotic-Antimycotic Solution (100x) Fisher Scientific Cat#15-240-096
AscI Restriction Enzyme New England Biolabs Cat#R0558S
b-Nicotinamide adenine dinucleotide (NAD+) 50 mM
solution
New England Biolabs Cat#B9007S
Bicine Sigma Cat#B8660-100G
Bio-Safe Coomassie Stain Bio-Rad Cat#1610786
BirA Ligase Özkan et al., 2013 N/A
Blotting-Grade Blocker Bio-Rad Cat#1706404
Bovine Serum Albumin Fraction V Roche Cat#03116956001
Bromophenol Blue Fisher Scientific Cat#BP115-25
Carbenicillin, disodium salt Sigma Cat#C1389-10G
cOmplete, EDTA-free Protease Inhibitor Cocktail Sigma Cat#5056489001
dNTP mix; 10 mM each Genscript Cat#C01582
d-Biotin Sigma Cat#B4501-5G
DTT Sigma Cat#D0632-25G
Expi293 Expression Medium Thermo Fisher Scientific Cat#A14635
ExpiFectamine Thermo Fisher Scientific Cat#A14635
Fetal Bovine Serum, ultra-low IgG Thermo Fisher Scientific Cat#16250078
FreeStyle 293 Expression Medium Thermo Fisher Scientific Cat#12338026
Glycerol Fisher Scientific Cat#BP229-4
HBS-P+ Buffer 10X GE Healthcare Cat#BR-1006-71
HEPES solution, 1 M, pH 7.0-7.6 Sigma Cat#H0887
Imidazole Acros Organics Cat#12202-5000
InstantBlue Protein Stain Expedeon Cat#ISB1L
LB Agar, Miller (Powder), 2 kg Fisher Scientific Cat#BP1425-2
Linear Polyethylenimine Fisher Scientific Cat#NC9197339
Invitrogen UltraPure Agarose Thermo Fisher Scientific Cat#16500500
Ethidium Bromide (1% Solution), 10 mL Fisher Scientific Cat#BP1302-10
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Luria-Bertani (LB) Broth (Miller) Sigma Cat#L3522-1KG
MACS buffer Miltenyi Cat#130-091-221
Magnesium acetate, hexahydrate Sigma Cat#M5661-250G
Magnesium chloride hexahydrate Sigma Cat#M9272-100G
MOPS NuPAGE SDS Running Buffer (20X) Thermo Fisher Scientific Cat#NP0001
Ni-NTA Agarose QIAGEN Cat#30250
NotI-HF Restriction Enzyme New England Biolabs Cat#R3189L
Opti-MEM Reduced Serum Thermo Fisher Scientific Cat#31985062
PEG-8000 Sigma Cat#81268-1KG
Phosphate Buffered Saline, pH 7.2 GIBCO Cat#20012-043
Phusion HF DNA Polymerase New England Biolabs Cat#M0530L
Propidium iodide Thermo Fisher Scientific Cat#P3566
Precision Plus Protein Dual Color Standards Bio-Rad Cat#1610374
Recombinant Human Angiopoietin-1 Protein, CF R&D Systems Cat#923-AN-025/CF
Recombinant Human b-NGF R&D Systems Cat#256-GF/CF
Recombinant Human Leptin Protein, CF R&D Systems Cat#398-LP-01M
Recombinant Mouse Leptin Protein, CF R&D Systems Cat#498-OB-01M
Recombinant protein A Thermo Fisher Scientific Cat#21184
SeeBlue Plus2 Pre-stained Protein Standard Thermo Fisher Scientific Cat#LC5925
Series S Sensor Chip SA GE Healthcare Cat#BR-1005-31
Sodium bicarbonate Fisher Scientific Cat#BP328-500
Sodium Chloride Fisher Scientific Cat#S271-3
Streptavidin Invitrogen Cat#S888
Superdex 200 Increase column GE Healthcare Cat#28990944
Superose S6 column GE Healthcare Cat#17-5172-01
T5 Exonuclease New England Biolabs Cat#M0363L
Taq Ligase New England Biolabs Cat#M0530L
Trans-Blot Turbo RTA Midi PVDF Transfer Kit Bio-Rad Cat#1704273
Tris base Fisher Scientific Cat#BP152-1
Tris-HCl Fisher Scientific Cat#BP153-1
Tween-20; Sigma Sigma Cat#P1379-500ML
Ultrapure SDS Life Technologies Cat#15525-017
Critical Commercial Assays
BCA Kit Pierce Cat#23227
KPL BluePhos Microwell Substrate Kit VWR Cat#95059-220
QIAQuick Gel Extraction Kit QIAGEN Cat#28506
QIAprep Spin Miniprep Kit QIAGEN Cat#27106
Deposited Data
Dryad This Study https://doi.org/10.5061/dryad.xsj3tx9bd
Experimental Models: Cell Lines
Expi 293F cells Thermo Fisher Scientific Cat#A14635; RRID: CVCL_D615
HEK293 Freestyle cells Thermo Fisher Scientific Cat#:R79007; RRID:CVCL_6642
Oligonucleotides
ISLR2 LRR1-7 forward: 50- CTGAGCTACATCTTC
TGCCTGGTGTTCGCTGCGGCCGCCTCTTGTCC
TGAACCTTGTGCCTGCG-30
This Study N/A
ISLR2 LRR1-7 reverse: 50- CCAGGCCC
TTGAAACAGAACTTCCAACCCCGGC
GCGCCAGGAGCGCAAGGCAGAGCAG-30
This Study N/A
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ISLR2 Ig1-3 forward: 50-CTGAGCTACATCTTC
TGCCTGGTGTTCGCTGCGGCCGCCCCTAGC
GTTCACCTGTCTGCC-30
This Study N/A
ISLR2 Ig1-3 reverse: 50-CCAGGCCCTTGAAAC
AGAACTTCCAACCCCGGCGCGCCAGAGGGC
AGCTCTTTCTTGGTGC-30
This Study N/A
pD649-HAsp-ECD-Fc(DAPA)-AviTag-6xHis
(sequencing) forward:50-ATTTAGGTGACACTATAG-30
This Study N/A
pD649-HAsp-ECD-Fc(DAPA)-AviTag-6xHis
(sequencing) reverse: 50-
CACGTACCAGTTGAACTTCACC-30
This Study N/A
Recombinant DNA
pD649-HAsp-ECD-Fc(DAPA)-AviTag-6xHis This study Addgene
pD649-HAsp-ECD-COMP5AP-AviTag-9xHis This study Addgene
pTT3-SP-6XHis-NTRK1(FL)-FLAG This study Addgene
pTT3-SP-6XHis-TIE1(FL)-FLAG This study Addgene
pTT3-SP-6XHis-PVR(FL)-FLAG This study Addgene
pTT3-SP-6XHis-KIR2DL5(FL)-FLAG This study Addgene
pTT3-SP-6XHis-KIR2DL4(FL)-FLAG This study Addgene
pTT3-SP-6XHis-KIR2DL1(FL)-FLAG This study Addgene
pTT3-SP-6XHis-ISLR2(FL)-FLAG This study Addgene
Software and Algorithms
Biacore T200 Control Software (version 3.2) GE Healthcare https://www.biacore.com/lifesciences/
service/downloads/downloads/index.html
BioGRID3.5 Oughtred et al., 2019 https://thebiogrid.org/
CytExpert 2.3 Beckman Coulter https://www.beckman.com/flow-cytometry/
instruments/cytoflex/software
FlowJo 10.4.2 FlowJo https://www.flowjo.com/
HUGO Gene Nomenclature Committee (HGNC) Yates et al., 2017 https://www.genenames.org/
Human Protein Atlas Uhlén et al., 2015 https://www.proteinatlas.org/
IntAct Orchard et al., 2014 https://www.ebi.ac.uk/intact/
Interactive Tree of Life (iTOL) (version 5.5) Letunic and Bork, 2019 https://itol.embl.de/
MAFFT (Multiple Alignment
using Fast Fourier Transform)
Kuraku et al., 2013; Katoh et al., 2019 https://mafft.cbrc.jp/alignment/server/
MUltiple Sequence Comparison by Log- Expectation
(MUSCLE)
Edgar, 2004 https://www.ebi.ac.uk/Tools/msa/muscle/
PredGPI Pierleoni et al., 2008 http://gpcr.biocomp.unibo.it/predgpi/pred.htm
SignalP-5.0 Almagro Armenteros et al., 2019 http://www.cbs.dtu.dk/services/SignalP/
SnapGene 5.1 GSL Biotech LLC https://www.snapgene.com/
STRING (version 11.0) Szklarczyk et al., 2019
SoftMax Pro Molecular Devices https://www.moleculardevices.com/products/
microplate-readers/acquisition-and-analysis-
software/softmax-pro-software
Freedom EVOware Standard (version 2.5) Service
Pack 3, Build 2.5.21.0
TECAN https://lifesciences.tecan.com/
software-freedom-evoware?
TMHMM2.0 Krogh et al., 2001 http://www.cbs.dtu.dk/services/TMHMM/
UniProt The UniProt Consortium https://www.uniprot.org/
Other
Econo-Pak Chromatography Column Bio-Rad Cat#7321011
12-Column Reservoirs Agilent Cat#201256-100
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12-Column Reservoirs Integra Cat#6361
96-well deep well plates USA Scientific Cat#1896-2110
96-well round-bottom plate Corning Cat#3799
AirOtop Enhanced Seal for Ultra Yield Fisher Scientific Cat#NC0063892
Aluminum Foil Seals Corning Cat#7200684
Amicon Ultra-4 Centrifugal Filter Unit EMD Millipore Cat#UFC805024
Amicon Ultra-15 Centrifugal Filter Unit EMD Millipore Cat#UFC901024
Hyperfilm ECL Sigma Cat#GE28-9068-39
Nunc clear flat-bottom maxisorp 384-well plates Thermo Fisher Scientific Cat#464718
Nunc clear flat-bottom maxisorp 384-well plates Thermo Fisher Scientific Cat#464718
Nunc clear flat-bottom maxisorp 96-well plates Thermo Fisher Scientific Cat#442404
PolarSeal E&K Scientific Cat#T592100
Rapid-Flow Sterile Disposable Filter Units with PES
Membrane; 250 ml (0.2 um)
Thermo Fisher Scientific Cat#168-0045
Rapid-Flow Sterile Disposable Filter Units with PES
Membrane; 50 ml (0.2 um)
Thermo Fisher Scientific Cat#564-0020
Rapid-Flow Sterile Disposable Filter Units with PES
Membrane; 1 L (0.2 um)
Thermo Fisher Scientific Cat#567-0020
Seahorse Single Cavity P.P. Pyramid Base Reservoirs Agilent Cat#201244-100
TECAN TP unfiltered 200 ul tips; Zymark MBP/Thermo Fisher Scientific Cat#923-261
TECAN TR unfiltered 100 ul tips; Zymark MBP/Thermo Fisher Scientific Cat#907-261
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ResourceRESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, K. Chris-
topher Garcia (kcgarcia@stanford.edu).
Materials Availability
Plasmids generated in this study (1,144 plasmids) will be deposited to Addgene (Addgene preassigned plasmid #s: 156487-157630).
Due to COVID-19 reduced Addgene lab capacity and the queue for accepting large deposits at this time, plasmids may not be avail-
able from Addgene until early 2021. Full plasmid sequences are included in Data S2.
Data and Code Availability
Information for all 564 proteins in screen including gene name, UniProt entry name, aliases, full-length protein sequence, ECD bound-
aries and sequence, superfamily, type (secreted, STM, multi-pass TM, and GPI-anchored), and predicted molecular weight of ECD-
Fc and ECD-5AP proteins is included in Data S1. Full plasmid sequences for all bait and prey constructs are included in Data S2. Data
for qualitative assessment of ECD-Fc and ECD-5AP levels in conditioned media by western blot and AP quantitation of ECD-5AP
conditioned media (relative AP activity; ng/ml) are included in Data S3. Screen data and multiple sequence alignement (MSA) files
have been deposited to Dryad (https://doi.org/10.5061/dryad.xsj3tx9bd) and are included in Data S4. SPR conditions for all
ligand-analyte pairs tested including ligand RU, maximum analyte concentration, analyte RU at maximum concentration, number
of analyte concentrations tested, injection time (seconds), injection rate (ml/minute), dissociation time (seconds), and regeneration
conditions are included in Data S5.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HEK293 Freestyle suspension cells were grown in FreeStyle 293 Expression Medium (Thermo Fisher Scientific) in a 37C, 5% CO2
incubator with 130 rpm shaking. Expi293F suspension cells were grown in Expi293 ExpressionMedium (Thermo Fisher Scientific) in a
37C, 5% CO2 incubator with 130 rpm shaking.Cell 182, 1027–1043.e1–e10, August 20, 2020 e4
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Selection of proteins and ECD prediction
Two lists of human IgSF proteins were generated using the HUGO Gene Nomenclature Committee (HGNC) database (https://www.
genenames.org/data/genegroup/#!/group/589) and the Human Protein Atlas (HPA) database (https://www.proteinatlas.org/
humanproteome/tissue/secretome). Lists were checked for overlap and a master list was generated using the HPA majority deci-
sion-based method (MDM). Metadata for all master list proteins was extracted from UniProt, and extracted signal peptide (SP)
and TM predictions were compared to the SIgnalP-5.0 (http://www.cbs.dtu.dk/services/SignalP/) (Almagro Armenteros et al.,
2019) and TMHMM2.0 prediction servers (http://www.cbs.dtu.dk/services/TMHMM/) (Krogh et al., 2001). SP and TM predictions
were used to map the ECD boundaries of cell-surface proteins. For glycosylphosphatidylinositol-anchored (GPI) proteins, PredGPI
(http://gpcr.biocomp.unibo.it/predgpi/) (Pierleoni et al., 2008) andmanual sequence analysis were used to predict the ECD boundary
upstream of the phospholipase cleavage site. ECD sequences containing a Cys residue within the C-terminal 10 amino acids were
manually analyzed to determine whether the Cys residue fell within the last protein domain, or within the linker region between the last
protein domain and the TM. In cases where the Cys residue was predicted to reside within the linker region, the ECD boundary was
adjusted to end at the residue preceding the Cys to prevent potential protein misfolding due to aberrant Cys-Cys disulfide bond for-
mation between this putatively unpaired Cys and Cys residues in the Ig domains of the Fc. Following ECD domain boundary predic-
tion, canonical protein sequences were extracted from UniProt and compiled for back translation and optimization by GeneArt/Life
Sciences Technology for gene synthesis (see below).
Amino acid sequence homology analysis
Mutliple sequence alignment (MSA) was performed as follows. ECD amino acid sequences were submitted to theMUltiple Sequence
Comparison by Log- Expectation (MUSCLE) (https://www.ebi.ac.uk/Tools/msa/muscle/) (Edgar, 2004) and Multiple Alignment
using Fast Fourier Transform (MAFFT) (https://mafft.cbrc.jp/alignment/server/) (Kuraku et al., 2013; Katoh et al., 2019) online re-
sources and analyzed using both first iteration and second iteration parameters (MUSCLE) and default parameters (MAFFT). Output
files were submitted to the Interactive Tree of Life (iTOL) (https://itol.embl.de/) (Letunic and Bork, 2019), an agglomerative hierarchical
clustering algorithm, to build a cluster hierarchy and generate phylogenetic trees. MSA files have been deposited to Dryad (https://
doi.org/10.5061/dryad.xsj3tx9bd).
Bait and prey expression plasmids
Genes encoding curated ECD and secreted proteins were synthesized at GeneArt/Life Sciences Technologies and subcloned into
both pD649-HAsp-ECD-Fc(DAPA)-AviTag-6xHis and pD649-HAsp-ECD-COMP5AP-AviTag-9xHis bait and prey expression vec-
tors, respectively. Genes were subcloned in-frame with the upstream hemagglutinin signal peptide (HAsp) (MKTIIALSYIFCLVFA)
and downstream Fc(DAPA)-AviTag-6xHis or COMP5AP-AviTag-9xHis modules via 50 NotI and 30 AscI sites. Bait expression vectors
fuse genes in-frame with the Fc region of human IgG containing D265A and P329A mutations (DAPA), followed by an AviTag
(GLNDIFEAQKIEWHE), and 6xHis. The DAPAmutation was used because it prevents binding of Fc receptors to the Fc. Prey expres-
sion vectors fuse the gene in-frame with a 3C enzyme cleavage site (LEVLFQGP), followed by the rat cartilage oligomeric matrix pro-
tein (COMP) pentamerization domain (Holler et al., 2000) fused to human placental alkaline phosphatase (5AP), an AviTag, and 9xHis.
A MaxiPrep of plasmid DNA was provided by GeneArt/Life Sciences Technologies at 1 mg/ml in 20 mM Tris, pH 8.0. For complete
plasmid sequences of all 564 bait and prey expression vectors, see Data S2.
ISLR2-Fc truncation expression plasmids
ECD-Fc expression vectors for two ISLR2 ECD truncations comprising: 1) the N-terminal seven LRRs (LRR1-7) and 2) the C-terminal
three Ig domains (Ig1-3) were generated by PCR amplification of the regions encoding these domains from pD649-HAsp-ISLR2-
Fc(DAPA)-AviTag-6xHis. Resulting PCR products were cloned into the NotI-AscI double-digested parental pD649-HAsp-ECD-
Fc(DAPA)-AviTag-6xHis backbone by isothermal assembly. LRR1-7 comprises amino acids 19-232 and Ig1-3 comprises amino
acids 233-589. Primer sequences are listed in the Key Resources Table. PCR products were run on an agarose gel (Thermo Fisher
Scientific) stained with ethidium bromide (Fisher Scientific), and purified using a QIAQuick Gel Extraction Kit (QIAGEN). Isothermal
assembly was performed using 1 mL digested plasmid DNA (50 ng/ml), 1-4 mL purified PCR product (80 ng/ml) and 15 mL isothermal
assembly mix. Isothermal assembly mix contained 320 mL 5X ITA buffer (0.5M Tris-HCl, pH 7.5, 50mMMgCl2, 1 mMdNTPmix (Gen-
script), 50mMDTT, 25%w/v PEG-8000, 0.33%w/v nicotinamide adenine dinucleotide (New England Biolabs)), 1 mL T5 exonuclease
(New England Biolabs), 20 mL Phusion HF DNA polymerase (New England Biolabs), 160 mL Taq ligase (New England Biolabs) and
700 mL Ultrapure H2O (EMD Millipore). Reactions were incubated at 50
C for 1 hour, transformed into competent DH5a cells
(Zymogen), plated on Luria-Bertani (LB) Broth agar (Fisher Scientific) plates containing 50 mg/ml carbenicillin (Sigma), and incubated
overnight at 37C. Colonies were picked into 8 mL LB (Sigma) containing 50 mg/ml carbenicillin and grown 18 hours at 37C with
250 rpm shaking. Plasmid DNA was purified using a QIAprep Spin Miniprep Kit (QIAGEN) and absorbance at 260 nm was measured
using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific) to determine plasmid DNA concentration. LRR1-7 and Ig1-3
sequences were confirmed by sequencing (MCLab) using primers listed in the Key Resources Table. For complete plasmid
sequences, see Data S2.e5 Cell 182, 1027–1043.e1–e10, August 20, 2020
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Genes encoding full-length proteins were synthesized at GeneArt/Life Sciences Technologies and subcloned into the pTT3 expres-
sion vector. Genes contain the endogenous signal peptide, a 6xHis tag (to facilitate cell-surface expression analysis), the remaining
full-length coding region of the gene, and a FLAG tag, followed by a stop codon. Synthesized DNA contained upstreamNotI and NheI
and downstream MluI and XbaI restriction sites. Synthesized DNA was subcloned into pTT3 using 50 NotI and 30 XbaI sites. A
MaxiPrep of plasmid DNA was provided by GeneArt/Life Sciences Technologies at 1 mg/ml in 20 mM Tris, pH 8.0. For transgene
sequences, see Data S2.
Conditioned media for standard ECIA
ECD-Fc bait and ECD-5AP prey conditioned media were produced in Expi293F suspension cells grown in Expi293 Expression Me-
dium (Thermo Fisher Scientific) in a 37C, 5%CO2 incubator with 130 rpm shaking. Transfection was performed using Expifectamine
as per manufacturer’s instructions (Thermo Fisher Scientific). Briefly, cells were grown to 4-5x106 cells/ml and diluted to 3x106 cells/
ml. 1 mg of plasmid DNA was used per ml of culture. Plasmid DNA was mixed with 1/20 transfection volume of OptiMem (Thermo
Fisher Scientific) and, in a separate tube, 2.7 mL Expifectamine/mg DNA was mixed with 1/20 transfection volume of OptiMEM. After
3 minutes incubation of Expifectamine with OptiMem at room temperature, solutions containing plasmid DNA and OptiMem were
mixed and incubated for 5 minutes at room temperature before adding dropwise to cells. Enhancer 1 and Enhancer 2 were added
18 hours later according to the manufacturer’s instructions. Three days following addition of Enhancers, cell cultures were har-
vested, and spun 7 minutes at 1,294 x g to pellet cells. Conditioned media was supplemented to 10% ultra-low IgG Fetal Bovine
Serum (Thermo Fisher Scientific) and 1X antibiotic-antimycotic solution (Fisher Scientific), and stored at 4C.
Conditioned media for apECIA screen
ECD-Fc bait and ECD-5AP prey conditioned media were produced using the Protein Expression and Purification Platform (PEPP), a
fully-automated suite of custom robotic platforms (Rue et al., 2019). PEPP is extensively described in a recent book chapter (Rue
et al., 2019). Briefly, HEK293 Freestyle cells were grown in FreeStyle 293 Expression Medium (Thermo Fisher Scientific). Cells
were cultured in custom-made flasks and transfected using linear polyethylenimine (PEI) (Fisher Scientific). Three days post-trans-
fection, cells were spun down, conditioned media was supplemented to 10% ultra-low IgG Fetal Bovine Serum (Thermo Fisher Sci-
entific), 1X antibiotic-antimycotic solution (Fisher Scientific) and cOmplete protease inhibitor (Sigma), 0.2 um filtered (Thermo Fisher
Scientific), and stored at 4C.
Western blot analysis of conditioned media
ECD-Fc bait and ECD-5AP prey conditioned media were analyzed by western blot against C-terminal 6xHis (bait) and 9xHis (prey)
tags to confirm all full-length proteins were of the expected size. Westerns were performed as follows: 10 mL of conditioned media
was combined with 2 mL of 6X SDS loading dye (Tris/SDS buffer (0.5 M Tris, pH 6.8, 0.4% SDS), 38% glycerol (weight/volume), 10%
(weight/volume) SDS, 0.55M 2-mercaptoethanol, 0.0024%bromophenol blue (weight/volume)). Samples were incubated at 95C for
3 minutes and run on a 4%–20% Mini-PROTEAN gel (Bio-Rad). 10 mL of 1 ng/ml FPLC-purified IL2-Fc was run as a concentration
standard on each gel. After running, gels were rinsed in dH2O and transferred to a PVDF membrane using the High MW setting
on a Bio-Rad TransBlot Turbo system using the Midi PVDF Transfer Kit (Bio-Rad) according to manufacturer’s instructions. Mem-
branes were blocked for 1-2 hours at room temperature with shaking in Western blocking buffer (20 mM Tris, pH 7.2, 0.5M NaCl,
0.2% Tween-20, 5% Blotting-Grade Blocker (Bio-Rad)). Penta-His antibody (QIAGEN) was added at 1:1000 and blots were incu-
bated at 4C overnight with shaking. Membranes were washed 10 times for 2 minutes on an orbital shaker at 300 rpm in Western
blocking buffer and stained in Western blocking buffer + 1:5000 HRP-tagged polyclonal rabbit anti-mouse antibody (Agilent) for
1-1.5 hours at room temperature on an orbital shaker at 70 rpm. Membranes were incubated with 4 mL ECL Prime Western Blotting
Detection Reagent (Fisher Scientific), exposed to HyperfilmECL, and developed on anAll-Pro 100 Plus X-ray film processor (ALLPRO
Imaging). Exposure times ranged from 5 s to 4 hours in order to adequately cover the wide range of expression levels of proteins
present in conditioned media.
To qualitatively assess protein levels we included a known concentration of a purified His-tagged reference protein, IL2-Fc. West-
erns were semiquantitatively analyzed by comparing the intensity of conditioned media bands with the IL2-Fc standard. If condi-
tioned media bands were visible at an intensity which could be directly compared with the standard, an estimate of the relative con-
centration of protein in the conditioned media could be determined from 0.1X to 10X of the standard. In cases where conditioned
media proteins were present at very high levels, in a short exposure where the standard was barely visible, it was scored
as > 10X. In cases where the conditioned media was barely visible while the standard band was overexposed, it was scored
as < 0.1x. In cases where the conditionedmedia bandwas barely visible at the longest exposure, it was denoted as ‘‘faint.’’ If a condi-
tioned media failed to show any band at the longest exposure (4 hours), it was scored as ‘‘undetectable.’’ Levels are reported in
Data S3.
AP quantitation of prey conditioned media
AP standards were prepared as follows: 2-fold dilutions (1.5625-800 pg/ml) of purified alkaline phosphatase (AP) (Thermo Fisher
Scientific) were prepared using 1X TBS (20mMTris pH 7.4, 150mMNaCl). AP standards (10 ml) and 1X TBS (10 ml; blank) were addedCell 182, 1027–1043.e1–e10, August 20, 2020 e6
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transfections (10 ml; blank) were also added in duplicate. 50 mL of BluePhos AP substrate (VWR) was added to all wells. O.D. 650 nm
was measured using a SpectraMax Paradigm plate reader (Molecular Devices) with SoftMax Pro software. Measurements were
taken at multiple time points (4-60 minutes) to obtain values within the linear range of various regions of the AP standard curve for
quantitation of ECD-5AP proteins exhibiting a broad spectrum of expression levels (relative AP activity: 5 ng/ml to 650 ng/ml). AP
quantitation results were in good agreement with qualitative Western estimates (Figure S1B). Complete quantitation results are re-
ported in Data S3.
6xHis tag purification of ECD-Fc protein
ECD-Fc proteins were produced in Expi293F cells using transfection conditions described above. Following harvesting of cell condi-
tioned media, 1 M Tris, pH 8.0 was added to a final concentration of 20 mM. Ni-NTA Agarose (QIAGEN) was added to 5%
conditioned media volume. 1 M sterile PBS, pH 7.2 (GIBCO) was added to 3X conditioned media volume. The mixture was stirred
overnight at 4C. Ni-NTA agarose beads were collected in a Buchner funnel and washed with 300 mL protein wash buffer (30 mM
HEPES, pH 7.2, 150 mM NaCl, 20 mM imidazole). Beads were transferred to an Econo-Pak Chromatography column (Bio-Rad) and
protein was eluted in 15 mL of elution buffer (30 mM HEPES, pH 7.2, 150 mM NaCl, 200 mM imidazole). Proteins were concentrated
using Amicon Ultracel 10K filters (Millipore) to a volume of0.5mL and absorbance at 280 nmwasmeasured using a Nanodrop 2000
spectrophotometer (Thermo Fisher Scientific) to determine protein concentration.
Biotinylation and FPLC purification
Proteins were biotinylated as described previously (Özkan et al., 2013). Briefly, up to 10mg of protein was incubated at 4 overnight in
2X Biomix A (0.5 M bicine buffer), 2X Biomix B (100 mM ATP, 100 mM MgOAc, 500 mM d-biotin), Bio200 (500 uM d-biotin) to a final
concentration of 20 uM, and 60-80 units BirA ligase in a final volume of 1 ml. Proteins were further purified by size-exclusion chro-
matography using an S200 Increase or a Superose S6 column (GE Healthcare), depending on protein size, on an ÄKTA Pure FPLC
(GE Healthcare). All proteins were eluted in 1X HBS (30 mM HEPES pH 7.2, 150 mM NaCl). Following elution, a sample from each
protein fraction was run on a 4%–20% Mini-PROTEAN gel and gels were Coomassie stained to check for protein degradation
and identify fractions containing intact protein for pooling of samples. 2 to 10 mL of peak sample fractions were mixed with 2 mL
6X loading dye (see above) in a final volume of 12 mL and incubated at 95C for 5 minutes prior to running on a 4%–20%Mini-PRO-
TEAN gel (Bio-Rad). Gels were briefly rinsed 3X in dH2O, incubated in warm dH2O for 10-15 minutes on an orbital shaker at 60 rpm to
fully remove residual SDS, then incubated 1 hour to overnight at room temperature with shaking in Bio-Safe Coomassie Stain (Bio-
Rad). Gels were briefly rinsed 3X in dH2O, then washed in dH2Owith shaking at room temperature for several hours to overnight prior
to imaging in a Bio-Rad Gel Doc EZ Imager (Bio-Rad). Fractions containing intact protein were pooled, concentrated using Amicon
Ultracel 10K filters (Millipore) to a volume of 100-300 mL and absorbance at 280 nm was measured as above. SEC data are shown in
Figure S5.
Strep-shift analysis of biotinylated proteins
1 to 10 mg of FPLC-purified protein was added to 3.7 mL 6X SDS loading dye (see above) in a final volume of 20 ml, incubated at 95C
for 5 minutes, then placed on ice for 10 minutes. Equal volumes of samples were split into two tubes. 4X molar excess of streptavidin
(Invitrogen) was added to one tube, and an equivalent volume of 1X HBS (30 mM HEPES pH 7.2, 150 mM NaCl) was added to the
other tube. Streptavidin was also added to an otherwise blank reaction containing 1X HBS and 6X SDS loading dye. Samples were
incubated on ice for 20 minutes prior to running on a 4%–20% Mini-PROTEAN gel (Bio-Rad). Binding of streptavidin to biotinylated
protein causes the molecular weight of the biotinylated protein to increase (shift) in molecular weight by 40 kD. The fraction of bio-
tinylated protein in the sample was estimated by comparing the intensity of the band in the no-streptavidin lanewith that of the shifted
band in the plus-streptavidin lane.
Optimization of ECIA in 384-well plates
Early pooling experiments were performed in a 96-well plate format. We noticed that when we moved to a 384-well plate format, the
sensitivity (maximum O.D. 650 nm signal) was 1.4-fold lower than observed in 96-well plates. We optimized three parameters to
increase the sensitivity in 384-well plates. To optimize the volume of BluePhos substrate (VWR), we added 4 mL of a 2-fold dilution
series (undiluted to 1/64 dilution) of ECD-5AP conditionedmedia or mock conditionedmedia tomultiple rows of a 384-well plate, and
added increasing volumes of BluePhos substrate (10 mL increments from 10 mL to 100 ml) (prepared according to manufacturer’s in-
structions). O.D. 650 nmwasmeasured at multiple time points (20minutes, 40minutes, 1 hour, 1.5 hours, 2 hours, and 3 hours) using
a SpectraMax Paradigm plate reader (Molecular Devices) with SoftMax Pro software. At low ECD-5AP concentrations, 40 mL and
60 mL of BluePhos substrate yielded maximum O.D. 650 nm values, while retaining minimal background signal (i.e., highest signal
to background ratio). Follow-up experiments were performed to fine-tune the volume of BluePhos substrate and 50 mL was found
to be the optimal volume for high signal to background. As the plate was read at multiple times following addition of BluePhos sub-
strate, this experiment also allowed us to optimize BluePhos substrate incubation time. The 2 hour time point yielded the highest
signal to background ratio (BluePhos oxidizes over time, thereby turning blue without recourse to enzymatic activity).e7 Cell 182, 1027–1043.e1–e10, August 20, 2020
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using conditionedmedia with different binding pairs exhibiting a range of binding levels fromweak to high (O.D. 650 nm values, 2-fold
to 40-fold over background signal). For theweakest binding pairs, 20 mL of bait and 20 mL of prey was required to obtainR 2-fold over
background signals (cutoff for categorizing a binding pair as a putative ‘‘hit’’).
ECIA using pooled prey
Pooled prey experiments were carried out in a 384-well clear NuncMaxiSorp plate (Thermo Fisher Scientific). Protein Awas diluted to
10 mg/ml (from a stock concentration of 10 mg/ml in 1X PBS, pH 7.4) in 100 mM sodium bicarbonate buffer, pH 9.6 and sterile filtered
(0.2 um). 20 mL of Protein A solution was added to each well and sealed plates (PolarSeal; E&K Scientific) were incubated at 4C over-
night. Protein A solution was removed and 90 mL blocking solution (1X TBST (20 mM Tris, pH 7.4, 150 mM NaCl, 0.05% w/v Tween-
20), 3%BSA) was added. Sealed plates were blocked at room temperature for 3 hours. Blocking buffer was removed and plates were
washed 3 times with 90 mL 1X TBST. 20 mL of ECD-Fc bait conditioned media (or mCherry-Fc control conditioned media) was added
to wells and sealed plates were incubated at 4C overnight. Plates were washed 3 times with 90 mL 1X TBST using an automated
HydroSpeed plate washer (TECAN). 20 mL of undiluted or 1:3 diluted ECD-5AP prey conditioned media was added and sealed plates
were incubated at room temperature overnight. Plates were washed 3 times with 90 mL 1X TBST and 50 mL of KPL BluePhos sub-
strate (VWR) was added (prepared according to manufacturer’s instructions). Following incubation for 2 hours at room temperature,
O.D. 650 nm was measured as above. Background was subtracted using the absorbance of mCherry-Fc control wells.
ECIA titration
Titration experiments were carried out in 96-well NuncMaxisorp plates as above with the followingmodifications. Increased volumes
were used including 100 mL 10 mg/ml Protein A solution, 200 mL 1X TBST wash buffer, 250 mL blocking solution, and 150 mL BluePhos
substrate (VWR). For ECD-Fc bait and ECD5-AP prey, 100 mL of undiluted or a 2-fold dilution series of conditioned media was used
(dilutions performed using mock conditioned media). As above, mCherry-Fc conditioned media was used for bait control wells.
ECIA testing of PVR binding to KIRs
ECIA in 96-well Nunc Maxisorp plates was carried out as above with the following modifications. Because specificity of PVR-5AP
prey binding was tested to many KIR-Fc bait family members, it was essential to ensure that all KIR-Fc well surfaces were saturated
to compare differences in binding to KIR-Fc proteins. To ensure KIR-Fc saturation, multiple applications of 150 mL of KIR-Fc condi-
tionedmedia were applied sequentially. Applications were incubated for 3 hours at room temperature before removal and addition of
the subsequent application. The last application was incubated at 4C overnight. To confirm KIR-Fc saturation of all wells, following
ECIA and O.D. 650 nm measurement, plates were washed 3 times with 200 mL 1X TBST. 50 mL 6X SDS loading dye (see above) was
added to each well and plates were placed at 20C. Plates were removed from 20C, allowed to thaw to room temperature and
placed on a 42C heat block for 20 minutes to assist in releasing protein from the plate surface. 10 mL was run on a 4%–20% Mini-
PROTEAN gel (Bio-Rad) and anti-His western blot was performed as above.
Design of robotic choreography for apECIA
Development of an automated platform required a design strategy that arranged bait and prey stock proteins in a format which al-
lowed all bait and pooled prey pairs to be combined by choreographed transfer into 384-well microtiter reaction plates using a liquid
handling system. 384-well plates are composed of 96 quadrants, each a 2x2 matrix. We utilized a 2x2 matrix scheme to test 384
unique combinations of bait and pooled prey in each plate. To achieve this, two bait proteins were arrayed in alternating rows. Pooled
prey proteins were transferred from two stock plates (X and Y, each containing 94 unique prey pools) into alternating columns in two
contiguous rows.
The 96-quadrant, 2x2matrix layout was achieved using a customized robotic workstation.We developed a choreographed robotic
workflow, and programmed robot methods to execute a two-step process for: 1) sample processing into distinct layouts to generate
bait and prey conditioned media stock plates and 2) all steps of screening in ELISA plates. The automated platform utilized two pi-
petting robotic arms with user-defined aspiration and dispense parameters for liquid speed and acceleration and deceleration of
plungers to ensure precision volume pipetting of samples with varying viscosity, and z axis control for non-contact pipetting. The first
is an 8-channel, fixed-tip, positive pressure liquid displacement handling arm (LiHa) with programmable features for sample aspira-
tion and dispense tracking, variable y-spacing, and individual channel control for x- and y-axis transfer of samples (‘‘cherry-picking’’).
The second is an air displacement multichannel dispensing arm (MCA) with 96-tip head for user-defined multi-tip transfer (‘‘stamp-
ing’’). The workstation includes a 3-axis plate transport robotic manipulator arm (RoMA) and integrates a PowerWasher PW384 plate
washer (TECAN) and Infinite M1000 multimodal spectrophotometer plate reader (TECAN). A wavelength of 650 nm was used to
detect the substrate absorbance of the BluePhos phosphatase substrate (KPL) used to detect protein interactions. To implement
real-time pipetting volume verification after addition of each reagent into 384-well reaction plates, each plate was also read at
980 nm as liquid volume (absorbance pathlength) for non-opaque aqueous solutions correlates with optical density at 980 nm
(McGown and Hafeman, 1998). Following both LiHa and MCA dispensing of every reagent into 384-reaction plates, we performed
volumeQC using automated spectrometry analysis. All automated liquid handling processes were carried out using TECANFreedom
Evo2 robotics workstations with in-house designed components for sample processing to allow larger volume sample handling.Cell 182, 1027–1043.e1–e10, August 20, 2020 e8
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Studies using ECIA and other variations of this assay have demonstrated that results are highly reproducible. As such, we performed
the pooled prey screen once and validated ‘‘hits’’ in triplicate. The screen was performed in 384-well plates using reagent volumes
determined by optimization experiments (see above). Each week 48 plates were screened (47 test plates and one control plate). Test
plates contained two ECD-Fc baits in alternating rows; as such, 94 baits were tested each week. The control plate contained alter-
nating rows of mCherry-Fc conditioned media and mock conditioned media. As prey were tested in pools of three, the 564 prey pro-
teins in the screen comprised 188 pools. Prey pools were distributed into two 96-deep well stock plates designated ‘‘X’’ and ‘‘Y,’’
each containing 94 prey pools. The remaining two wells contained positive control preys for testing to positive control baits located
in eight wells in the bottom right corner of each plate (wells M23-24, N23-24, O23-24 and P23-24). Controls included four bait-prey
pairs in duplicate wells including a non-binding, low binding, intermediate binding, and strong binding pair. Using a 96-tip stamping
method, prey pools from plate ‘‘X’’ were transferred to 384-well ELISA plates in two subsequent rows within each of the odd-
numbered columns. Prey pools from plate ‘‘Y’’ were similarly transferred into two subsequent rowswithin each of the even-numbered
columns.
Each week 96 baits were tested (94 test baits, mCherry-Fc and mock) against all prey pools (and 4 prey controls) in 48 plates
totaling 18,432 reaction wells. As 94 test baits were tested against all 564 preys, 53,016 bait-prey combinations were tested per
week. We conducted the screen in 6 weeks testing 318,096 combinations (i.e., 53,016 3 6 = 318,096), the total number in a matrix
of 564 proteins (i.e., 5643 564 = 318,096). Screen data are available at Dryad (https://doi.org/10.5061/dryad.xsj3tx9bd) andData S4.
apECIA screen deconvolution and validation
Nine of the 188 prey pools gave rise to large numbers of wells with positive signal (R2-fold over background) and were excluded as
non-specific PPIs. Following removal of wells representing non-specific PPIs, the 756 wells with the highest fold-over-background
signal were selected for deconvolution. Background was calculated using the average signal of each prey pool against all 564 baits
and controls (mCherry-Fc and mock). Deconvolution was performed for each well by re-testing bait with each of the three pool prey
proteins in separate wells. The 756 wells selected for deconvolution included wells exhibiting the highest signal (> 50 fold-over-back-
ground) down to wells with a nominal signal (1.3 fold-over-background). We chose to deconvolute wells with such a low signal due to
the possibility that actual PPIs may have yielded nominal signals as a result of decreased prey concentration brought about by pool-
ing. In such cases, re-screening against undiluted prey may result in higher signal and identification of an otherwise missed PPI (false
negative). Deconvolution revealed 495 wells with signalR 2 fold-over-background. In each case, only one of the three deconvoluted
prey yielded a positive binding signal, referred to as the ‘true-binding’ prey. To confirm binding, each ‘true-binding’ prey was re-
tested against its partner bait in triplicate and against a negative control bait (mCherry-Fc). All re-tested bait-prey PPI pairs exhibited
binding signal R 2 fold-over-background. To determine whether PPIs were known, we searched the literature using PubMed and
Google Scholar, and the PPI databases STRING (Szklarczyk et al., 2019), BioGRID3.5 (Oughtred et al., 2019), and IntAct (Orchard
et al., 2014). In addition to human, we considered PPIs reported in mouse, rat, and zebrafish to be known.
Cell-surface binding assay
To examine PPIs at the cell surface, we performed cell-surface protein binding assays. Expi293F cells were transfected as abovewith
expression plasmids encoding full-length proteins containing an N-terminal 6xHis tag (following the signal peptide, see above). Two
days following transfection, cultures were harvested, cells were spun down for 4min at 1600 rpm (400 x g), and resuspended in cold
MACS buffer (Miltenyi) to a final density of33106 cells/ml. To generate tetramerized ECD-Fc ligands to test for binding to cells ex-
pressing full-length proteins, FPLC-purified biotinylated ECD-Fc proteins (see above) were incubated with streptavidin tetramers
conjugated to Alexa Fluor 647 (SA-647) (Thermo Fisher Scientific) at a 4:1 molar ratio on ice for at least 15 minutes. To assess
cell-surface expression of full-length proteins, 1:100 mouse anti-His-647 antibody (R&D Systems) staining of cells was also per-
formed in parallel. Approximately 150,000 cells were incubated with ECD-Fc:SA-647 complexes or antibody in a final volume of
100 mL in 96-well round-bottom plates (Corning) for 1 hour at 4C protected from light. Two-fold dilutions series of ECD-Fc:SA-
647 complexes were performed. Depending on the experiment, final ECD-Fc:SA-647 complex concentrations (when incubated
with cells) ranged from 31.25 nM to 4000 nM (PVR-Fc:SA-647, KIR2DL5-Fc:SA-647, TrkA-Fc:SA-647: 31-4000 nM; leptin-Fc:SA-
647: 16-2000 nM). For staining of full-length KIR2DL5-, KIR2DL4- and KIR2DL1-transfected cells, 250 nM PVR-Fc:SA-647 was
used. Mock transfected cells were used as a negative control and TCR/OTII-Fc protein was used as a negative control ligand for
staining. Following incubation, cells were washed two times with 200 mL cold MACS buffer and resuspended in 120 mL cold
MACS buffer with 1:200 propidium iodide (Thermo Fisher Scientific). Immunofluorescence staining was analyzed using a Cytoflex
(Beckman Coulter) and data were collected for 20,000 cells. Data were analyzed using FlowJo v10.4.2 software. All data report me-
dian fluorescence intensity (MFI). Concentration-dependent binding of ECD-Fc:SA-647 to full-length receptor-expressing, but not
mock control cells, was deemed indicative of cell-surface binding.
SPR experiments
SPR experiments were performed using a Biacore T200 instrument (GE Healthcare). Biotinylated ECD-Fc proteins (ligands) were
sequentially purified using nickel-NTA and FPLC (see above) and captured on a Streptavidin (SA) Series S Sensor Chip (GE Health-
care). Chip capture was performed in HBS-P+ buffer (GEHealthcare) aiming for300-700 ligand response units (RU). Flow cell 1 wase9 Cell 182, 1027–1043.e1–e10, August 20, 2020
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Resourceleft empty to use as a reference flow cell for on-line subtraction of bulk solution refractive index and for evaluation of non-specific
binding of analyte to the chip surface using Biacore T200 Control Software (version 3.2) (GE Healthcare). In most cases, test ligands
were captured in flow cells 2 and 3. A ligand for which binding was not expected was captured in flow cell 4 to serve as a negative
control. Except where noted, FPLC-purified unbiotinylated ECD-Fc protein was used as analyte. Analytes were run in HBS-P+ buffer
using 2-fold increasing protein concentrations to generate a series of sensorgrams. Since ECD-Fc analyte proteins were presented in
a bivalent form (due to dimerization by the Fc-domain), sensorgrams followed a bivalent binding model which is not suitable for
deriving a single binding constant for straightforward numerical quantification of the binding interaction. Nonetheless, these sensor-
grams could be used to derive a qualitative assessment of binding since they represent an increasing response profile with increasing
analyte concentrations, and below threshold response to the negative control ligand. The validation of interactions using bivalent
analyte proteins allowed us to verify interactions that, in their monovalent form,may exhibit extremely fast kinetics and off-rateswhich
would have been difficult, if not impossible, to capture without this avidity enhancement. Commercially-available monomer analytes
used for SPR included recombinantmouse and human leptin (R&DSystems), recombinant human b-NGF (R&DSystems) and recom-
binant human angiopoietin-1 (R&D Systems). SPR conditions for each analyte-ligand pair tested including ligand RUs, analyte RUs,
concentration range of 2-fold analyte dilutions, injection rate, injection and dissociation times and regeneration conditions are pro-
vided in Data S5.
QUANTIFICATION AND STATISTICAL ANALYSIS
Alkaline phosphatase enzymatic activity
Data from standard ECIA and apECIA in duplicate and triplicate reaction wells, respectively, are reported as mean of background
subtracted values ±SDor asmean of fold-over-background ±SD (indicated in legends), where backgroundwasmeasured by testing
prey binding to a negative control bait(s), mCherry-Fc and/or mock conditionedmedia (Figures 1C, 4C, 5C, 5G, 6E, and 6G; Data S4).
Prey levels in conditioned media were quantitated from duplicate reaction wells against a standard curve of purified alkaline phos-
phatase and mean values from duplicate reaction wells are reported (Figures S1B, S1C, and S4F; Data S3).
Cell binding assay
Data were collected for 20,000 cells in duplicate reactions and analyzed using FlowJo v10.4.2 software. Values are reported as me-
dian fluorescence intensity (MFI) (Figures 5 and 6).
Statistical analysis of number of PPIs
Statistical analysis of the expected versus observed PPIs (Figure 1F) was performed using the Kolmogorov–Smirnov (K-S) test, a
non-parametric and distribution-free test with no assumption of data distribution.Cell 182, 1027–1043.e1–e10, August 20, 2020 e10
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Figure S1. Bait and Prey Levels in Conditioned Media, Related to Figure 1 and Data S3
(A) Qualitative levels of bait (left) and prey (right) proteins in conditioned media used for screen as assessed by western blot against C-terminal 6xHis and 9xHis
tags, respectively. Levels were estimated by comparing band intensity of proteins to a purified ECD-Fc standard on each gel. Un; undetectable.
(B) Qualitative prey levels in conditioned media (panel A) versus quantitative relative AP activity (ng/ml), as determined by AP enzymatic assay. Black lines
denote mean.
(C) Relative AP activity (ng/ml), as determined by AP enzymatic assay, for all prey used in pooling experiments. Prey levels span the entire spectrum, from themax
AP levels obtained in conditioned media (Rst: 659 ng/ml) using our expression system down to levels below quantitation (bql).
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Figure S2. Identification of Non-specific PPIs in Screen, Related to Data S3 and S4
(A) Left. Screen results for 564 3 564 matrix showing positive wells (R2-fold over background). White, previously known PPI; orange, previously unknown PPI;
red, non-specific PPI. Right. Screen results following removal of non-specific PPIs. Non-specific PPIs may result from misfolded proteins. Freq, frequency.
(B) Number of positive wells (R2-fold over background) in the screen for each of the 188 prey pools. Prey pools with > 16 positive wells (above red dotted line)
were classified as ‘‘sticky,’’ potentially exhibiting non-specific binding. In the screen, 16 PPIs for Siglec-10 were observed, many of which were PPIs with other
Siglec subfamilymembers. Asmany Siglec-Siglec PPIs were observed in the screen, Siglec-10’s 16 PPIs were determined to not be the result of ‘‘stickiness,’’ and
16 PPIs was selected as a conservative cut-off for non-specific ‘‘sticky’’ prey tominimize the possibility of including false positives in the PPI dataset. Each prey in
the screenwas individually tested against mCherry-Fc bait andmock controls (data not shown) and positive binding signals were used to identify the ‘‘sticky’’ prey
in each pool which were excluded from the PPI dataset. Table shows the protein expression level of the nine ‘‘sticky’’ prey in the conditioned media used for the
screen. Qualitative expression levels were assessed by western blot.
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Figure S3. Distribution of PPIs between Protein Families, Related to Figure 1 and Data S1 and S4
Pie graph showing the number of PPIs between proteins belonging to different families. Proteins categorized as ‘‘other’’ include non-IgSF DEATH domain re-
ceptors and cytokines, among others. IgSF; immunoglobulin superfamily. TNFSF; tumor necrosis factor superfamily.
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Figure S4. Distribution of Bait and Prey Expression and Dynamic Range, Related to Data S3 and S4
(A) Number of bait proteins engaging in one to > 5 PPIs by qualitative expression level as assessed by western blot.
(B) Number of prey proteins engaging in one to > 10 PPIs by qualitative expression level as assessed by western blot.
(C) Number of PPIs involving bait proteins that were undetectable in conditioned media by western blot.
(D) Number of PPIs involving prey proteins that were undetectable in conditioned media by western blot and quantitative AP enzymatic assay.
(E) Known PPIs involving bait or prey proteins that were undetectable in conditioned media by western blot (bait and prey) and quantitative AP enzymatic assay
(prey). PPIs listed are the only PPIs observed in the screen for these undetectable bait and prey proteins. Red font, undetectable protein.
(F) Relative AP activity (ng/ml) versus binding affinity (nM) for 34 known PPIs observed in the screen with published KD values to illustrate the dynamic range of
apECIA. PPIs that fall outside the dynamic range (orange perimeter), which is determined by the combined effect of PPI affinity and bait and prey concentrations,
will likely result in false negatives (box with gray slashes). Blue shaded bars (colors as in panels A and B) represent qualitative prey protein levels as determined by
western blot. Red dotted line segregates prey that were both undetectable by Western and below the quantitation limit (bql) using the AP enzymatic assay. The
break in the x axis is to emphasize that data points to the left of the break (bql) could not be quantitated and, as such, are all positioned vertically in the center of the
gray bar.
ll
Resource
Figure S5. Size-Exclusion Chromatography of ECD-Fc Bait Proteins, Related to Figures 3, 4, 5, and 6 and STAR Methods
FPLC traces of ECD-Fc proteins used for SPR and cell-surface binding experiments.
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Figure S6. SPR Validation of LAR-PTPR, IL1AP, and PD-L2 PPIs, Related to Figure 4 and Table 1
(A) SPR sensorgrams for PTPRF-Fc and PTPRD-Fc analytes (2-fold dilutions; 2-2048 nM) binding to SALM1/2/3/4/5 ECD-Fc.
(B) SPR sensorgrams for PTPRF-Fc and PTPRS-Fc analytes (2-fold dilutions; 2-2048 nM) binding to IL1RAP-Fc, IL1RAPL1-Fc and IL1RAPL2-Fc ligands.
(C) SPR sensorgrams for PD-L1-Fc analyte (2-fold dilutions; 16-16000 nM) binding to PD-L1-Fc, PD-L2-Fc and PD-1-Fc ligands. TIE1-Fc ligand, negative control.
RU; resonance units.
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Figure S7. Control SPR Experiments for TIE2 and Leptin-LEPR, Related to Figure 6
(A) SPR sensorgrams for Trk-Fc analyte (2-fold dilutions; 2-2048 nM) and monomer angiopoietin-1 analyte (2-fold dilutions; 2-1024 nM) binding to TIE1-Fc and
TIE2-Fc ligands. As TIE2-Fc ligand showed no binding to TrkA-Fc analyte, monomer angiopoietin-1 analyte was included as a positive control for TIE2-Fc ligand.
(B) SPR sensorgrams for monomer human leptin analyte (2-fold dilutions; 0.39-12.5 nM) and monomer mouse leptin analyte (2-fold dilutions; 0.39-6.25 nM)
binding to human LEPR-Fc and mouse Lepr-Fc ligands. Kd values are shown. TIE1-Fc ligand, negative control.
RU; resonance units.
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